Several clinical trials have investigated the antitumour effect of bisphosphonates when used as adjuvant treatment for early stage breast cancer. Among these, the results of the AZURE trial, although negative, highlight the potential benefit of treatment with zoledronic acid in postmenopausal women with high-risk early stage breast cancer.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Structural simulation of adenosine phosphate via plumbagin and zoledronic acid competitively targets JNK/Erk to synergistically attenuate osteoclastogenesis in a breast cancer model
Cell Death & Disease Open Access 11 February 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Mathew, A. & Brufsky, A. Bisphosphonates in breast cancer. Int. J.Cancer http://dx.doi.org/10.1002/ijc.28965 (2014).
Clezardin, P. Potential anticancer properties of bisphosphonates: insights from preclinical studies. Anticancer Agents Med. Chem. 12, 102–113 (2012).
Paterson, A. H. et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol. 13, 734–742 (2012).
Coleman, R. et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol. 15, 997–1006 (2014).
Coleman, R. et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann. Oncol. 24, 398–405 (2013).
Brufsky, A. M. et al. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 118, 1192–1201 (2012).
Gnant, M. et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 12, 631–641 (2011).
Coleman R. et al. Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: a meta-analysis of individual patient data from randomised trials [abstract]. Cancer Res. 73 (Suppl.), aS4–07 (2013).
Saad, F. et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann. Oncol. 23, 1341–1347 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Mathew, A., Brufsky, A. Zoledronic acid—more than just a bone drug. Nat Rev Clin Oncol 11, 564–565 (2014). https://doi.org/10.1038/nrclinonc.2014.152
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2014.152
